ライフサイエンスコーパス: coronary artery disease

1 stenosis and low to intermediate-complexity coronary artery disease.

2 n of patients with known or suspected stable coronary artery disease.

3 irin (ASA) desensitization for patients with coronary artery disease.

4 mpared with MT alone in patients with stable coronary artery disease.

5 the potent P2Y12 inhibitors in patients with coronary artery disease.

6 cluding hypertension, diabetes mellitus, and coronary artery disease.

7 phoma Kinase) is linked to a protection from coronary artery disease.

8 links to BMI, adiposity-related traits, and coronary artery disease.

9 , bipolar disorder, Alzheimer's disease, and coronary artery disease.

10 s in patients with multivessel and left main coronary artery disease.

11 old balloon angioplasty in the management of coronary artery disease.

12 c plaque, which may be a subsequent risk for coronary artery disease.

13 n hypercholesterolemic pigs with preexisting coronary artery disease.

14 utpatients (age: 63+/-9 years; 76% men) with coronary artery disease.

15 stitutes a serious problem for subjects with coronary artery disease.

16 edical therapy (OMT) for patients with known coronary artery disease.

17 This paper reports on patients with coronary artery disease.

18 enotypes of patients with known or suspected coronary artery disease.

19 ody weight affects outcomes in patients with coronary artery disease.

20 re, cardiac masses, pericardial disease, and coronary artery disease.

21 tient-tailored strategy for the treatment of coronary artery disease.

22 ic morphologic and physiologic assessment of coronary artery disease.

23 pen-label clinical trial in 50 patients with coronary artery disease.

24 patients with chest pain and nonobstructive coronary artery disease.

25 d in epicardial AT of humans with or without coronary artery disease.

26 vasive coronary angiography and had no known coronary artery disease.

27 xpression of their genetic susceptibility to coronary artery disease.

28 precursor have been associated with risk of coronary artery disease.

29 e, 89% white race, and 12% with a history of coronary artery disease.

30 on revascularization in patients with stable coronary artery disease.

31 r against each other in patients with stable coronary artery disease.

32 onary physiology in the modern management of coronary artery disease.

33 hemorrhagic shock in swine with preexisting coronary artery disease.

34 complications in the presence of underlying coronary artery disease.

35 pressure-lowering treatment in patients with coronary artery disease.

36 h significant or suggestive association with coronary artery disease.

37 or evaluating patients with suspected stable coronary artery disease.

38 recludes assessing physiological severity of coronary artery disease.

39 G for the treatment of unprotected left main coronary artery disease.

40 for PCI with OMT versus OMT alone for stable coronary artery disease.

41 utpatients (age: 63+/-9 years; 76% men) with coronary artery disease.

42 AIS patients had no angiographic evidence of coronary artery disease.

43 large cohort of patients suspected of having coronary artery disease.

44 raphy, as compared with patients with stable coronary artery disease.

45 ain at least 90% of the attributable risk of coronary artery disease.

46 cibility of FFRangio in patients with stable coronary artery disease.

47 disease in comparison with controls without coronary artery disease.

48 relevance for patients with risk factors or coronary artery disease.

49 Prevalence of obstructive coronary artery disease (1%-64%), ACS (1%-44%), downstre

50 vation myocardial infarction and multivessel coronary artery disease: 1-stage percutaneous coronary i

51 rtension (77%), diabetes mellitus (31%), and coronary artery disease (15%).

52 were sudden arrhythmic death syndrome (31%), coronary artery disease (22%), and hypertrophic cardiomy

53 agnosis of cardiovascular disease, including coronary artery disease (26.6 to 12.6% of admissions) an

54 nsion (47 % and 31 % vs 15 %, P < 0.001) and coronary artery disease (29 % and 18 % vs 3 %, P < 0.001

55 test declining primary cardiac diagnosis was coronary artery disease (32.3%-19.0%; P<0.001).

56 n DNA sequence variants for association with coronary artery disease (4,831 cases and 115,455 control

57 were common, including hypertension (82.5%), coronary artery disease (42.6%), and diabetes mellitus (

58 Main comorbidities included coronary artery disease (51.5%), renal insufficiency (27

59 gists by 2 1 method required the presence of coronary artery disease, a common interpretation of the

60 e kidney transplantation commonly focuses on coronary artery disease, a comprehensive pretransplant c

61 s associated with mortality in patients with coronary artery disease, a finding that is independent o

62 INTERPRETATION: In patients with stable coronary artery disease, addition of rivaroxaban to aspi

63 ors of potentially fatal arrhythmias without coronary artery disease admitted to our institutions fro

64 Antiplatelet therapy is of proven benefit in coronary artery disease and a number of other clinical s

65 found to be appropriate because obstructive coronary artery disease and ACS were more prevalent in p

66 Among patients who had multivessel coronary artery disease and acute myocardial infarction

67 Cardiac risk was assessed by noting baseline coronary artery disease and calculating the WHO/Internat

68 e 4-BRS was also associated with severity of coronary artery disease and composite end points.

69 21.3 region are consistently associated with coronary artery disease and coronary artery calcificatio

70 Patients with stable coronary artery disease and DM exhibit a burden of angin

71 ated loci for Alzheimer's disease, eight for coronary artery disease and five for type 2 diabetes.

72 Coronary artery disease and flail leaflet were seen in 1

73 iously reported significant association with coronary artery disease and GRS153 of 153 single-nucleot

74 onal cardiologists to assess the severity of coronary artery disease and guide treatment, coronary an

75 r mixed methods investigation (compared with coronary artery disease and hypertension).

76 Among patients with documented stable coronary artery disease and in whom no revascularization

77 Coronary artery disease and its risk factors are some of

78 becoming increasingly popular in the area of coronary artery disease and its risk factors, many of th

79 other or medical treatment in patients with coronary artery disease and left ventricular ejection fr

80 istics of published mixed methods studies on coronary artery disease and major risk factors (diabetes

81 ated to treatment (two in the control group [coronary artery disease and multiorgan failure] and thre

82 ty patients with a low pretest likelihood of coronary artery disease and normal findings on stress pe

83 he context of a recent GWAS meta-analysis of coronary artery disease and provide a list of targeted e

84 atins have been used for 30 years to prevent coronary artery disease and stroke.

85 robiota-dependent metabolite associated with coronary artery disease and stroke.

86 Dyslipidemia is an important risk factor for coronary artery disease and stroke.

87 we describe GWAB-boosted candidate genes for coronary artery disease and supporting data in the liter

88 BMI, systolic blood pressure, coronary artery disease and type 2 diabetes showed negat

89 revent sudden cardiac death in patients with coronary artery disease and unstable ventricular tachyar

90 T are associated with more atherosclerosis, coronary artery disease, and cardiovascular events.

91 ified by age, sex, risk factors, presence of coronary artery disease, and early presentation.

92 ion, hypercholesterolemia, family history of coronary artery disease, and known coronary artery disea

93 outh), BMI, height, systolic blood pressure, coronary artery disease, and type 2 diabetes using data

94 Epicardial adipose tissue volume and coronary artery disease are strongly associated, even af

95 intervention (PCI) for radiation-associated coronary artery disease are unknown.

96 nically, CVD in this population manifests as coronary artery disease, arrhythmias, stroke, or congest

97 Although virtually all coronary artery disease associated single-nucleotide pol

98 ients were older, with a lower prevalence of coronary artery disease, atrial fibrillation, and diabet

99 lead AAA single nucleotide polymorphisms and coronary artery disease, blood pressure, lipids, or diab

100 ally attributable to an elevated subclinical coronary artery disease burden composed of noncalcified

101 computed tomographic angiography to quantify coronary artery disease burden.

102 y is an important tool for the evaluation of coronary artery disease but often correlates poorly with

103 medical therapy (MT) in patients with stable coronary artery disease, but PCI was guided by angiograp

104 ated with lower risks of type 2 diabetes and coronary artery disease, but their relations with interm

105 ance imaging, after exclusion of obstructive coronary artery disease by angiography.

106 liter) (P=1.0x10(-16)), and a lower risk of coronary artery disease (by 34%; 95% confidence interval

107 sterol, low-density lipoprotein cholesterol, coronary artery disease, C-reactive protein, HbA1c, heig

108 tion and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics; combined total 6

109 ce standard for the functional assessment of coronary artery disease (CAD) ( 1 , 2 ).

110 We also conduct parallel investigations for coronary artery disease (CAD) (viewed as a positive cont

111 The prevalence of coronary artery disease (CAD) among patients with refrac

112 ave identified multiple loci associated with coronary artery disease (CAD) among predominantly Europe

113 nd local site interpretation for significant coronary artery disease (CAD) and cardiovascular events.

114 lated with QTc prolongation in patients with coronary artery disease (CAD) and investigate the effect

115 to elevated serum calcium levels and risk of coronary artery disease (CAD) and myocardial infarction

116 c factor with therapeutic potential to treat coronary artery disease (CAD) and myocardial infarction

117 obstructive (>/=50% stenosis) left main (LM) coronary artery disease (CAD) are at high risk for adver

118 The value of coronary artery disease (CAD) assessment and coronary in

119 Genome-wide association studies (GWAS) in coronary artery disease (CAD) had identified 66 loci at

120 ) trial, patients with 3-vessel or left main coronary artery disease (CAD) had improved long-term out

121 for determining the presence and severity of coronary artery disease (CAD) in patients with sign and

122 Coronary artery disease (CAD) is a chronic inflammatory

123 RATIONALE: Coronary artery disease (CAD) is a complex phenotype dri

124 Coronary artery disease (CAD) is a leading cause of morb

125 Coronary artery disease (CAD) is a significant problem d

126 asive testing for a diagnosis of significant coronary artery disease (CAD) is ambiguous, but nuclear

127 gher for women than for men, yet obstructive coronary artery disease (CAD) is less prevalent in women

128 Coronary artery disease (CAD) is the leading cause of de

129 Coronary artery disease (CAD) is the number one cause of

130 Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown.

131 ovided a rich collection of approximately 58 coronary artery disease (CAD) loci that suggest the exis

132 oninvasive models to predict the presence of coronary artery disease (CAD) may help reduce the societ

133 ne, has mechanistic links to atherosclerotic coronary artery disease (CAD) pathogenesis and is associ

134 tly associated with cardiovascular events in coronary artery disease (CAD) patients and reducing the

135 n stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive test

136 e molecular off-target effects and increased coronary artery disease (CAD) risk.

137 sought to describe an optimized approach to coronary artery disease (CAD) screening and management i

138 Coronary artery disease (CAD) severity was quantified in

139 dawned for the prevention and management of coronary artery disease (CAD) utilizing genetic risk var

140 METHODS AND Obstructive coronary artery disease (CAD) was defined as >/=50% sten

141 Comorbid coronary artery disease (CAD) was present in 24.3% of vi

142 rmediate pretest probability for obstructive coronary artery disease (CAD) were randomly assigned to

143 ion could beneficially affect progression of coronary artery disease (CAD) when compared with transpl

144 for atherosclerosis, the underlying cause of coronary artery disease (CAD), a major cause of morbidit

145 re among the most robust genetic markers for coronary artery disease (CAD), and previous studies have

146 causes, any CVD, atherosclerotic CVD (ACVD), coronary artery disease (CAD), and stroke.

147 ants influencing cholesterol levels, risk of coronary artery disease (CAD), body mass index, as well

148 2+)-activated K(+) channels in subjects with coronary artery disease (CAD), but its mechanisms of act

149 elated with lifespan while susceptibility to coronary artery disease (CAD), cigarettes smoked per day

150 Among patients with coronary artery disease (CAD), improvement of lifestyle-

151 scribed Chinese medicine for both stroke and coronary artery disease (CAD), its underlying common mol

152 etically higher calcium had a higher risk of coronary artery disease (CAD), myocardial infarction (MI

153 eneity has already been well investigated in coronary artery disease (CAD), the knowledge about monoc

154 status has been related to increased risk of coronary artery disease (CAD), which is a condition that

155 dial infarction (MI) in patients with stable coronary artery disease (CAD).

156 ng studies among patients without history of coronary artery disease (CAD).

157 eating Peripheral Vascular Disease (PVD) and Coronary Artery Disease (CAD).

158 ts, nor if such results indicate obstructive coronary artery disease (CAD).

159 cytokine in inflammatory diseases, including coronary artery disease (CAD).

160 e (MR) perfusion imaging in the detection of coronary artery disease (CAD).

161 -hip ratio (WHR) with mortality and incident coronary artery disease (CAD).This study followed 130,47

162 s displayed lower TC and were protected from coronary artery disease (CAD); (ii) excluding the CETP l

163 olocalize with known susceptibility loci for coronary artery disease (CARDIoGRAMplusC4D) and large ar

164 nome-wide Replication and Meta-analysis plus Coronary Artery Disease (CARDIoGRAMplusC4D) consortium.

165 In patients with coronary artery disease, clinical outcome depends on the

166 In a coronary artery disease cohort separate from volunteers

167 e women having a lower burden of obstructive coronary artery disease compared with men, the prevalenc

168 pain and had a lower pretest probability of coronary artery disease compared with men.

169 outcomes in relation to diabetic status and coronary artery disease complexity as assessed by the Sy

170 cording to drug-eluting stent generation and coronary artery disease complexity were performed.

171 ension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabe

172 y conditions include venous thromboembolism, coronary artery disease, congestive heart failure, sleep

173 undergoing initial evaluation for suspected coronary artery disease, coronary CTA was associated wit

174 larization decisions in patients with stable coronary artery disease could be improved by assessment

175 re were 6 patients with positive findings of coronary artery disease detected on MDCT coronary angiog

176 transplantation and coronary bypass grafts, coronary artery disease, diabetic cardiomyopathy, hypert

177 Prevalent coronary artery disease did not increase the risk to die

178 istory of coronary artery disease, and known coronary artery disease), each gram increase of posterio

179 CT coronary angiography revealed positive coronary artery disease findings in 16 patients; LAD was

180 Among participants with coronary artery disease, fluctuation in body weight was

181 .G202V HAND2 variant associated with CHD and coronary artery diseases found in a large Lebanese famil

182 uidelines-Stroke and Get With The Guidelines-Coronary Artery Disease from 2006 to 2009 and treating >

183 SS trial, of whom 24 824 patients had stable coronary artery disease from 558 centres.

184 In patients with hypertension and coronary artery disease from routine clinical practice,

185 -wide Replication and Meta-analysis Plus the Coronary Artery Disease Genetics (CardiogramplusC4D) con

186 t disease (CHD) data from CARDIoGRAMplusC4D (Coronary Artery Disease Genome-wide Replication and Meta

187 s (N = up to 61079 individuals) and from the Coronary Artery Disease Genome-wide Replication and Meta

188 sted for their combined effect on CAD in the Coronary Artery Disease Genome-Wide Replication and Meta

189 Consortium and 194,427 participants from the Coronary ARtery DIsease Genome-wide Replication and Meta

190 e 51+/-8.8 years), 80 (6.5%) had obstructive coronary artery disease (>/=70% stenosis) and 68 (5.5%)

191 c arrest in nearly half of survivors in whom coronary artery disease had been excluded.

192 Eligible patients with coronary artery disease had to have had a myocardial inf

193 th systolic heart failure that is not due to coronary artery disease has been based primarily on subg

194 symptomatic systolic heart failure caused by coronary artery disease has been well documented.

195 In vitro, MSCs from individuals with coronary artery disease have reduced ability to suppress

196 men, despite having less severe angiographic coronary artery disease, have an increased risk of targe

197 prognostic ability of these risk markers in coronary artery disease, heart failure, and atrial fibri

198 with medical therapy alone, in patients with coronary artery disease, heart failure, and severe left

199 were followed through December 31, 2012, for coronary artery disease, heart failure, and stroke.

200 ril 1, 2002, without prior valvular disease, coronary artery disease, heart failure, cardiac arrhythm

201 e, lower systolic blood pressure, history of coronary artery disease, heart failure, chronic obstruct

202 spital size, teaching hospital status, known coronary artery disease, heart failure, diabetes mellitu

203 l dysfunction, hypertension (HTN), diabetes, coronary artery disease, history of atrial arrhythmias,

204 nfarction in the past 20 years, multi-vessel coronary artery disease, history of stable or unstable a

205 Cs) are promising therapeutic strategies for coronary artery disease; however, donor-related variabil

206 for time of enrollment, age, sex, history of coronary artery disease, hypertension, and diabetes.

207 ier modelling in respect of the diagnosis of coronary artery disease in 197 study subjects and the pr

208 uccessful treatment of unstable, multivessel coronary artery disease in a child with PCI with BRS imp

209 ant implications for the future treatment of coronary artery disease in children and warrants further

210 ters in epicardial AT of human patients with coronary artery disease in comparison with controls with

211 Few studies have assessed the prevalence of coronary artery disease in masters athletes with a low a

212 e efforts have been made to directly measure coronary artery disease in this vulnerable population.

213 erved probability of CED with a CREST score (coronary artery disease, initial heart rhythm, low eject

214 Coronary artery disease is a major cause of morbidity an

215 ing process of ACS patients with obstructive coronary artery disease is associated with a high reclas

216 iac arrest or periarrest without significant coronary artery disease is crucial for management and pr

217 ment in the delivery of OMT to patients with coronary artery disease is one possible step to help the

218 Coronary artery disease is the leading global cause of m

219 ridaforolimus for treatment of patients with coronary artery disease is undetermined.

220 nd cardiovascular disease due to accelerated coronary artery disease is well established.

221 of known history for obstructive epicardial coronary artery disease, is associated with reduced MFR

222 comes in patients with unprotected left main coronary artery disease (LMCAD) treated with coronary ar

223 a better prognosis than MI with obstructive coronary artery disease (MI-CAD).

224 al noninvasive testing to evaluate suspected coronary artery disease might affect subsequent clinical

225 n risk for five vascular diseases, including coronary artery disease, migraine headache, cervical art

226 potential to provide valuable biomarkers for coronary artery disease mirroring especially alterations

227 stable outpatients presenting with suspected coronary artery disease, most patients experiencing clin

228 (PCI) in diabetic patients with multivessel coronary artery disease (MV-CAD).

229 red between men and women with either stable coronary artery disease (n=320) or acute coronary syndro

230 or dyslipidemia; family history of premature coronary artery disease; never smoking; symptoms unrelat

231 Patients with nonobstructive coronary artery disease (NOCAD; wall irregularities, ste

232 Among patients with coronary artery disease, nurse-coordinated referral to a

233 icantly less likely than noncarriers to have coronary artery disease (odds ratio, 0.81; 95% confidenc

234 m VTE genetic risk score was associated with coronary artery disease (odds ratio, 1.08; 95% confidenc

235 factors, have the lowest reported levels of coronary artery disease of any population recorded to da

236 signed 1905 eligible patients with left main coronary artery disease of low or intermediate anatomica

237 yield to identify patients with obstructive coronary artery disease on subsequent invasive coronary

238 PCI between 2005 and 2014 because of stable coronary artery disease or acute coronary syndrome were

239 ents undergoing PCI in the setting of stable coronary artery disease or acute coronary syndromes.

240 ngina pectoris OR acute coronary syndrome OR coronary artery disease OR cardiomyopathy.

241 ema AND stroke OR cerebrovascular disease OR coronary artery disease OR heart failure OR myocardial i

242 F or at risk of HF, such as in patients with coronary artery disease or hypertension.

243 lled, outpatient trial, patients with stable coronary artery disease or peripheral artery disease wer

244 ASA sensitivity with known/suspected stable coronary artery disease or presenting with an acute coro

245 th out-of-hospital cardiac arrest have shown coronary artery disease or symptoms during the hour befo

246 g subgroups of patients at increased risk of coronary artery disease or those with a specific driving

247 cular disease (OR, 0.10; 95% CI, 0.01-0.78), coronary artery disease (OR, 0.37; 95% CI, 0.20-0.67), a

248 Subjects without a history of stroke, coronary artery disease, or peripheral artery disease we

249 ean dose; hazard ratio, 1.03/Gy; P = .002,), coronary artery disease ( P < .001), and WHO/Internation

250 ictors of adverse cardiovascular outcomes in coronary artery disease patients.

251 dies suggest that among patients with stable coronary artery disease, patients with diabetes mellitus

252 etes, chronic obstructive pulmonary disease, coronary artery disease, peripheral arterial disease, hy

253 gnificance of smoking in relation to genetic coronary artery disease predisposition may merit further

254 ic role of elevated WBC across a spectrum of coronary artery disease presentations are warranted.

255 ients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST-segment-e

256 55+/-10 years), mostly with an intermediate coronary artery disease probability, between cardiac CT

257 iation of biological therapy with changes in coronary artery disease progression, measured by repeate

258 mparison to Functional Testing for Suspected Coronary Artery Disease) prospectively randomized 350 pa

259 larization) at 1 year in 2,008 patients with coronary artery disease randomized to BVS versus cobalt-

260 hemorrhagic shock in swine with preexisting coronary artery disease reduced renal dysfunction and ca

261 table, symptomatic outpatients without known coronary artery disease referred for noninvasive testing

262 en symptomatic patients without a history of coronary artery disease referred for SPECT and CAC scori

263 ere is angiographic evidence for obstructive coronary artery disease, remains unknown.

264 hletes with atherosclerotic risk factors for coronary artery disease report higher coronary artery ca

265 Although much less frequent than in adults, coronary artery disease requiring revascularization may

266 s familial hypercholesterolemia and unstable coronary artery disease requiring revascularization.

267 e genetic association between rs11556924 and coronary artery disease risk by characterizing its effec

268 Conventional coronary artery disease risk factors might potentially e

269 t population of the Bolivian Amazon with few coronary artery disease risk factors, have the lowest re

270 e-industrial lifestyle and low prevalence of coronary artery disease risk factors, we examined the Ts

271 lipoprotein (LDL) has been shown to increase coronary artery disease risk in hemodialysis patients, b

272 similar age, sex, and low Framingham 10-year coronary artery disease risk scores with an echocardiogr

273 en genome-wide significantly associated with coronary artery disease risk.

274 s of inflammation may translate into reduced coronary artery disease risk.

275 clinical outcomes among patients with stable coronary artery disease (SCAD) treated medically.

276 to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrh

277 ion (T2MI2007); and 1 method did not require coronary artery disease, the 2012 universal definition (

278 gulating protein] gene increases the risk of coronary artery disease, the leading cause of death worl

279 n scanning showed that CCDC92 likely affects coronary artery disease through insulin resistance pathw

280 ing the total number of loci associated with coronary artery disease to 95 at the time of analysis.

281 reserve with best MT in patients with stable coronary artery disease to assess clinical outcomes and

282 redicted lower BMI, systolic blood pressure, coronary artery disease, type 2 diabetes, and taller sta

283 In patients with coronary artery disease undergoing elective PCI, an incr

284 65.2+/-7.6 years) with exertional angina and coronary artery disease underwent cardiac catheterizatio

285 le patients (n = 4,057) without a history of coronary artery disease underwent CZT SPECT MPI.

286 a prospective study, 85 patients with stable coronary artery disease underwent percutaneous coronary

287 an initial investigation of suspected stable coronary artery disease using coronary CTA resulted in a

288 k prediction and management of patients with coronary artery disease warrants further study.

289 pt for those 31 to 35 years of age, for whom coronary artery disease was the most common finding.

290 s for diabetic patients who have multivessel coronary artery disease, we combine the results of the F

291 agnosed from 1997 to 2012 without history of coronary artery disease were identified using Danish nat

292 history of statin intolerance, diabetes, or coronary artery disease were not eligible.

293 rmediate pretest probability for obstructive coronary artery disease were randomized to FT (exercise

294 ls (90% on statins) with no prior history of coronary artery disease who had a screening CACS >/=300

295 Patients with severe coronary artery disease with a clinical indication for r

296 carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of

297 nts with stable single-vessel or multivessel coronary artery disease with reduced fractional flow res

298 diagnostic strategy for women with suspected coronary artery disease, with potential benefits in term

299 cantly from those of trials with multivessel coronary artery disease without left main LMCA stenosis.

300 antially reduce morbidity and mortality from coronary artery disease worldwide.